Skip to main content
Log in

Erkrankungen des Gastrointestinaltrakts unter medikamentöser Immunmodulation

Gastrointestinal tract diseases induced by medications

  • Schwerpunkt: Immunpathologie
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Nebenwirkungen von Medikamenten im Gastrointestinaltrakt sind zwar häufig, jedoch meist passager und wenig gefährdend. Bei nur wenigen schwerwiegenderen Verläufen wird eine Endoskopie notwendig und eine histologische Begutachtung veranlasst. Durch die Zunahme der Medikamentenzahl insbesondere im Bereich der Onkologie sieht sich der Pathologe mit neuen, über die klassischen Pathologien chronischer oder akuter Darmerkrankungen hinausgehenden Veränderungen konfrontiert. Diese können bekannte Erkrankungen imitieren oder Veränderungen hervorrufen, die einem neuen Phänotypen entsprechen. Im folgenden Beitrag sollen hier histologische Veränderungen von medikamenteninduzierten Erkrankungen des Darms vorgestellt werden, wobei in Einklang mit dem Themengebiet der Fokus auf Medikamente gelegt wird, die entweder direkt eine immunologische Reaktion auslösen oder durch Kompromittierung des Immunsystems sekundär zu einer gastrointestinalen Erkrankung führen.

Abstract

Gastrointestinal symptoms are common side effects of medical drugs. They are usually mild but sometimes require diagnostic endoscopy and histologic evaluation. Due to the rapidly increasing number of drugs developed especially for cancer treatment, pathologists are faced with a spectrum of different drug-associated histologies in all segments of the gastrointestinal tract. Some medication-induced mucosal damage features may mimic classical pathologies of nondrug-associated diseases, while others result in novel phenotypes. The present article focusses on the histologic presentations of gastrointestinal diseases induced by medications that either compromise or induce immune response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3a, b
Abb. 4

Literatur

  1. Ben-Horin S (2011) Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 61(2):327. https://doi.org/10.1136/gutjnl-2011-300398

    Article  PubMed  Google Scholar 

  2. Detweiler CJ, Mueller SB, Sung AD et al (2018) Brincidofovir (CMX001) toxicity associated with epithelial Apoptosis and crypt drop out in a Hematopoietic cell transplant patient: challenges in distinguishing drug toxicity from GVHD. J Pediatr Hematol Oncol 40(6):e364–e368. https://doi.org/10.1097/mph.0000000000001227

    Article  PubMed  Google Scholar 

  3. Goetz M, Atreya R, Ghalibafian M et al (2007) Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 13:1365–1368

    Article  Google Scholar 

  4. Hammami MB, Al-Taee A, Meeks M et al (2017) Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease. Clin J Gastroenterol 10:142–146

    Article  Google Scholar 

  5. Hashimoto S, Saitoh H, Wada K et al (1995) Pneumatosis cystoides intestinalis after chemotherapy for hematological malignancies: report of 4 cases. Intern Med 34:212–215

    Article  CAS  Google Scholar 

  6. Khalil PN, Huber-Wagner S, Ladurner R et al (2009) Natural history, clinical pattern, and surgical considerations of pneumatosis intestinalis. Eur J Med Res 14:231–239

    Article  Google Scholar 

  7. Kokkinidis DG, Bosdelekidou EE, Iliopoulou SM et al (2017) Emerging treatments for ulcerative colitis: a systematic review. Scand J Gastroenterol 52:923–931

    CAS  PubMed  Google Scholar 

  8. Lee J, Kim MS, Kim EY et al (2008) Mycophenolate mofetil promotes down-regulation of expanded B cells and production of TNF-alpha in an experimental murine model of colitis. Cytokine 44:49–56

    Article  CAS  Google Scholar 

  9. Logan C, Beadsworth MB, Beeching NJ (2016) HIV and diarrhoea: what is new? Curr Opin Infect Dis 29:486–494

    Article  Google Scholar 

  10. Machado ER, Carlos D, Sorgi CA et al (2011) Dexamethasone effects in the Strongyloides venezuelensis infection in a murine model. Am J Trop Med Hyg 84:957–966

    Article  CAS  Google Scholar 

  11. Makino Y, Tani C, Miyokawa N et al (2015) Multiple intestinal ulcers associated with primary Epstein-Barr virus infection in a patient with rheumatoid arthritis undergoing Methotrexate therapy. Intern Med 54:2855–2851

    Google Scholar 

  12. Mcdonald HH, Moore M (2017) Strongyloides stercoralis Hyperinfection. N Engl J Med 376:2376

    Article  Google Scholar 

  13. Pecoraro A, Nappi L, Crescenzi L et al (2018) Chronic diarrhea in common variable Immunodeficiency: a case series and review of the literature. J Clin Immunol 38:67–76

    Article  Google Scholar 

  14. Rubio-Tapia A, Herman ML, Ludvigsson JF et al (2012) Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87:732–738

    Article  CAS  Google Scholar 

  15. Saraei M, Hosseinbigi B, Shahnazi M et al (2014) Fatal Strongyloides hyper-infection in a patient with myasthenia gravis. Infection 42:1039–1042

    Article  CAS  Google Scholar 

  16. Segarra-Newnham M (2007) Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 41:1992–2001

    Article  CAS  Google Scholar 

  17. Soldini D, Gaspert A, Montani M et al (2014) Apoptotic enteropathy caused by antimetabolites and TNF-alpha antagonists. J Clin Pathol 67:582–586

    Article  CAS  Google Scholar 

  18. Star KV, Ho VT, Wang HH et al (2013) Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. Am J Surg Pathol 37:1319–1328

    Article  Google Scholar 

  19. Tashiro Y, Goto M, Takemoto Y et al (2006) Epstein-Barr virus-associated enteritis with multiple ulcers after stem cell transplantation: first histologically confirmed case. Pathol Int 56:530–537

    Article  Google Scholar 

  20. Umetsu SE, Brown I, Langner C et al (2018) Autoimmune enteropathies. Virchows Arch 472:55–66

    Article  CAS  Google Scholar 

  21. Varma P, Falconer J, Aga A et al (2017) Rituximab-induced Crohn’s disease. Scand J Gastroenterol 52:606–608

    Article  CAS  Google Scholar 

  22. Vieth M, Montgomery E (2017) Medication-associated gastrointestinal tract injury. Virchows Arch 470:245–266

    Article  CAS  Google Scholar 

  23. Weber A, Marques-Maggio E (2013) Apoptotic colonopathy under immunosuppression: mycophenolate-related effects and beyond. Pathobiology 80:282–288

    Article  CAS  Google Scholar 

  24. Wei JP, Wu XY, Gao SY et al (2016) Misdiagnosis and Mistherapy of Crohn’s disease as intestinal tuberculosis: case report and literature review. Medicine (Baltimore) 95(1):e2436. https://doi.org/10.1097/md.0000000000002436

    Article  Google Scholar 

  25. Wright NJ, Wiggins T, Stubbs BM et al (2011) Benign pneumatosis intestinalis with pneumoperitoneum and typhlitis: side-effects of drug or disease induced immunosuppression. BMJ Case Rep 2011. https://doi.org/10.1136/bcr.07.2011.4518

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Bläker.

Ethics declarations

Interessenkonflikt

H. Bläker gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von dem Autor durchgeführten Studien an Menschen oder Tieren.

Additional information

Schwerpunktherausgeber

W. Roth, Mainz

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bläker, H. Erkrankungen des Gastrointestinaltrakts unter medikamentöser Immunmodulation. Pathologe 39, 571–575 (2018). https://doi.org/10.1007/s00292-018-0478-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-018-0478-y

Schlüsselwörter

Keywords

Navigation